



Discussion points:

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis

Clinical considerations

- What do you think of the findings of the Cochrane review?
 - The authors of the review used individual patient data, collecting information on each of the nearly 3,500 women in 15 randomised trials, and did not have data from ten trials with more than 1,100 patients. Does this increase or decrease your confidence in the strength of the result?
 - The review highlights the effect of treatment on survival and disease-free survival at five years. Is this a reasonable length of follow-up for discussion with your patients?

- How should this review influence decisions about treatment for a woman with cervical cancer?
 - Will the precision of the results on the benefits of chemoradiotherapy help when discussing this treatment option with patients?
 - Do you regard the 6% reduction in deaths by five years after diagnosis as a large, moderate or small difference? How would you describe this effect to your patients, and how would they perceive it?
 - Does this review open up more options for the optimal chemoradiotherapy regimen for a particular patient, for example by showing the benefits of non-platinum-based therapy?

- Would other information help in making a decision about treating women with cervical cancer?
 - What extra information would you like to have on long-term toxicity?
 - Where might you get this information, if it is not available in the randomised trials?